VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb†or the "company†), a leading global eye health company dedicated to helping people see better to live better, today announced that it allocated a $2,802,125,000 tranche (the "Replacement Term Loans†) of new term B loans, the proceeds of which will be used to refinance all of its outstanding term B loans due 2031 (the "Third Amendment Term Loans†) and its outstanding term B loans due 2028 (the "First Increment ...

​Bausch + Lomb Corporation (NYSE:BLCO) is one of the Best Up and Coming Canadian Stocks to Buy. Wall Street has a cautious outlook on the stock despite an 8.59% increase in share price during the month. ​On November 13, Bausch + Lomb Corporation (NYSE:BLCO) highlighted its growth strategy at investor day. The management noted they have increased their focus on simplification and rebuilt the culture to embrace AI and technological innovation. The company unveiled that it targets 5% to 7% CAGR through 2028, ...

Core Message - The company is outlining a three-year plan aimed at achieving profitable growth and improving financial margins by approximately 600 basis points over the next three years [2][4]. Financial Strategy - The plan includes a focus on financial excellence, with a commitment to grow above market rates and enhance margins through various initiatives [2]. - The company aims to modernize its manufacturing footprint, which has been described as somewhat outdated, to create efficiencies in manufacturing and supply chain [5]. Business Segments - The surgical segment is expected to be the largest contributor to margin expansion, particularly through the introduction of higher premium intraocular lenses and implants [4]. - The company is also focusing on a diverse product mix across its consumer, pharmaceuticals, and surgical businesses to drive higher-margin products through its pipeline and R&D efforts [3]. Capital Allocation and M&A - The company is adopting a disciplined capital allocation approach, with a focus on small M&A and licensing, primarily for intellectual property to develop new medicines or products [6]. - There is a commitment to achieve a leverage ratio of three to three and a half times by 2028, aiming for an investment-grade credit rating [6]. Impact of Tariffs - Tariffs are impacting the company by approximately 40 basis points of margin this year, equating to about $20 million, primarily due to reciprocal tariffs affecting exports to China and Europe [7][8]. - The company is planning to shift some production from the U.S. to Europe and Asia in response to these tariffs [9][10]. Future Outlook - The company is preparing for a long-term environment of tariffs, indicating that it is planning around a new baseline for revenue impacted by tariffs [12]. - There are ongoing concerns about myopia in children due to screen time, and the company is developing a contact lens specifically designed for kids that incorporates therapeutic correction [20].

Core Insights - Bausch + Lomb Corporation will hold an investor day on November 13, 2025, at the New York Stock Exchange [1] - Chairman and CEO Brent Saunders will provide an update on the company's transformation and strategic outlook [1] - Executive Vice President and Chief Financial Officer Sam Eldessouky will share details on a three-year plan to drive sustainable growth [1]

Core Viewpoint - Bausch + Lomb Corporation is set to release its third-quarter financial results on October 29, 2025, and will provide a business update during a conference call and live webcast [1] Financial Results - The third-quarter financial results will be discussed in detail during the conference call scheduled for 8 a.m. ET on the release date [1] Investor Relations - All relevant materials regarding the financial results and business update will be available on the Investor Relations section of the Bausch + Lomb website prior to the conference call [1]

Group 1 - Acadia Healthcare Company, Inc. (ACHC) has been added to the Zacks Rank 5 (Strong Sell) List due to a 1.5% downward revision in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Bausch + Lomb Corporation (BLCO) is also on the Zacks Rank 5 (Strong Sell) List, with a 6% downward revision in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Concrete Pumping Holdings, Inc. (BBCP) has seen a significant 70.8% downward revision in the Zacks Consensus Estimate for its current year earnings over the last 60 days, leading to its inclusion in the Zacks Rank 5 (Strong Sell) List [2]